These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37743689)

  • 1. Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study.
    Van't Oever RM; Zwiers C; de Haas M; le Cessie S; Lopriore E; Oepkes D; Verweij EJTJ
    BJOG; 2024 May; 131(6):769-776. PubMed ID: 37743689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion.
    Vlachodimitropoulou E; Garbowski M; Anne Solomon S; Abbasi N; Seaward G; Windrim R; Keunen J; Kelly E; Van Mieghem T; Shehata N; Ryan G
    Br J Haematol; 2022 Feb; 196(4):1096-1104. PubMed ID: 34862601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape.
    de Winter DP; Kaminski A; Tjoa ML; Oepkes D
    BMC Pregnancy Childbirth; 2023 Jan; 23(1):12. PubMed ID: 36611144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation.
    Lindenburg IT; van Kamp IL; van Zwet EW; Middeldorp JM; Klumper FJ; Oepkes D
    BJOG; 2013 Jun; 120(7):847-52. PubMed ID: 23551577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal outcomes following intrauterine transfusion for hemolytic disease of the fetus and newborn: a twenty-year service review.
    Blyth U; Larsson M; Baird A; Waring G; Athiraman N
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):10220-10225. PubMed ID: 36121063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term follow up after intra-Uterine transfusionS; the LOTUS study.
    Verduin EP; Lindenburg IT; Smits-Wintjens VE; van Klink JM; Schonewille H; van Kamp IL; Oepkes D; Walther FJ; Kanhai HH; Doxiadis II; Lopriore E; Brand A
    BMC Pregnancy Childbirth; 2010 Dec; 10():77. PubMed ID: 21122095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study.
    Liu S; Ajne G; Wikman A; Lindqvist C; Reilly M; Tiblad E
    Acta Obstet Gynecol Scand; 2021 Dec; 100(12):2216-2225. PubMed ID: 34476807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease.
    Voto LS; Mathet ER; Zapaterio JL; Orti J; Lede RL; Margulies M
    J Perinat Med; 1997; 25(1):85-8. PubMed ID: 9085208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intrauterine blood transfusion: Status report of 4years of practice in France (2011-2014)].
    Girault A; Friszer S; Maisonneuve E; Guilbaud L; Cortey A; Jouannic JM
    J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):119-124. PubMed ID: 28403966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion.
    Nwogu LC; Moise KJ; Klein KL; Tint H; Castillo B; Bai Y
    Transfusion; 2018 Mar; 58(3):677-684. PubMed ID: 29250791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. School performance and behavioral functioning in children after intrauterine transfusions for hemolytic disease of the fetus and newborn.
    Ree IMC; van 't Oever RM; Jansen L; Lopriore E; de Haas M; van Klink JMM
    Early Hum Dev; 2021 Jun; 157():105381. PubMed ID: 33962361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Intrauterine Transfusion Interval and Perinatal Outcomes in Alloimmunized Pregnancies: Time-to-Event Survival Analysis.
    Snelgrove JW; D'Souza R; Seaward PGR; Windrim R; Kelly EN; Ryan G
    Fetal Diagn Ther; 2019; 46(6):425-432. PubMed ID: 31195389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programme.
    Slootweg YM; Koelewijn JM; van Kamp IL; van der Bom JG; Oepkes D; de Haas M
    BJOG; 2016 May; 123(6):955-63. PubMed ID: 26661943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of compensatory erythropoiesis in hemolytic disease of the fetus and newborn due to intrauterine transfusions.
    Ree IMC; Lopriore E; Zwiers C; Böhringer S; Janssen MWM; Oepkes D; De Haas M
    Am J Obstet Gynecol; 2020 Jul; 223(1):119.e1-119.e10. PubMed ID: 31978433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal necrotizing enterocolitis following intrauterine transfusions: is there an association?
    Rao SC; Patole SK; Dickinson JE; Reid KP; Doherty DA
    J Matern Fetal Neonatal Med; 2004 Jul; 16(1):51-4. PubMed ID: 15370083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management.
    Slootweg YM; Lindenburg IT; Koelewijn JM; Van Kamp IL; Oepkes D; De Haas M
    Am J Obstet Gynecol; 2018 Oct; 219(4):393.e1-393.e8. PubMed ID: 30063902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation.
    Vlachodimitropoulou E; Lo TK; Bambao C; Denomme G; Seaward GR; Windrim R; Tessier F; Kelly E; Van Mieghem T; Ryan G
    Br J Haematol; 2023 Jan; 200(1):100-106. PubMed ID: 36100813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999.
    van Kamp IL; Klumper FJ; Meerman RH; Oepkes D; Scherjon SA; Kanhai HH
    Acta Obstet Gynecol Scand; 2004 Aug; 83(8):731-7. PubMed ID: 15255845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus.
    Schonewille H; Klumper FJ; van de Watering LM; Kanhai HH; Brand A
    Am J Obstet Gynecol; 2007 Feb; 196(2):143.e1-6. PubMed ID: 17306657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal hematocrit decrease after repeated intravascular transfusions in alloimmunized pregnancies.
    Lobato G; Soncini CS
    Arch Gynecol Obstet; 2007 Dec; 276(6):595-9. PubMed ID: 17572904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.